{"id":3596655,"date":"2022-04-01T06:45:00","date_gmt":"2022-04-01T10:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/"},"modified":"2025-03-07T23:39:59","modified_gmt":"2025-03-08T04:39:59","slug":"merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/","title":{"rendered":"Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children"},"content":{"rendered":"<div class=\"q4default\">\n<p>    KENILWORTH, N.J.&#8211;(BUSINESS WIRE)&#8211;<br \/>\nMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date of the supplemental biologics license application (sBLA) for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in infants and children to July 1, 2022. The FDA requested additional analyses of data from the pediatric studies, which Merck has submitted to the FDA. No new studies have been requested by the FDA.\n<\/p>\n<p>\nIn December 2021, Merck announced that the FDA accepted the company\u2019s application for VAXNEUVANCE for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age and it was granted Priority Review.\n<\/p>\n<p>\n\u201cWe are confident in the strength of the data from our pediatric studies with VAXNEUVANCE and will continue to work expeditiously with the FDA to bring this important vaccine forward to infants and children in the United States as soon as possible,\u201d said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories.\n<\/p>\n<p>\n  <b>About VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)<\/b>\n<\/p>\n<p>\nVAXNEUVANCE, Merck\u2019s 15-valent pneumococcal conjugate vaccine, consists of purified capsular polysaccharides from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to CRM197 carrier protein. VAXNEUVANCE is indicated for active immunization of adults 18 years of age and older for the prevention of invasive disease caused by the S. pneumoniae serotypes contained in the vaccine. It is currently under investigation in the pediatric population. VAXNEUVANCE previously received Breakthrough Therapy designation and Priority Review from the FDA for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age.\n<\/p>\n<p>\n  <b>Select Safety Information for VAXNEUVANCE in Adults 18 Years of Age and Older<\/b>\n<\/p>\n<p>\nDo not administer VAXNEUVANCE to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.\n<\/p>\n<p>\nSome individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.\n<\/p>\n<p>\nThe most commonly reported solicited adverse reactions in individuals 18 through 49 years of age were: injection site pain (75.8%), fatigue (34.3%), myalgia (28.8%), headache (26.5%), injection site swelling (21.7%), injection site erythema (15.1%) and arthralgia (12.7%).\n<\/p>\n<p>\nThe most commonly reported solicited adverse reactions in individuals 50 years of age and older were: injection site pain (66.8%), myalgia (26.9%), fatigue (21.5%), headache (18.9%), injection site swelling (15.4%), injection site erythema (10.9%) and arthralgia (7.7%).\n<\/p>\n<p>\nVaccination with VAXNEUVANCE may not protect all vaccine recipients.\n<\/p>\n<p>\n  <b>About Merck<\/b>\n<\/p>\n<p>\nFor over 130 years, Merck, known as MSD outside the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals \u2013 including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases \u2013 as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=52639165&amp;newsitemid=20220401005105&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=01b0abdeb4f959dc8df92ba579954321\">vip2-msd.com\/merckcom-migrated<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=52639165&amp;newsitemid=20220401005105&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=51ccb789c523ad5d48e8bab86b29c707\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=52639165&amp;newsitemid=20220401005105&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=403f20decf17c2314b3e12808d9c7616\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=52639165&amp;newsitemid=20220401005105&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=f07dcf0653e66d73c71cfad06408514f\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=52639165&amp;newsitemid=20220401005105&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=f2eaf26148e3ce7bf79cbff240399933\">YouTube<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=52639165&amp;newsitemid=20220401005105&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=44f9680d3aeb329f5f226b166cb0e63f\">LinkedIn<\/a>.\n<\/p>\n<p>\n  <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n<\/p>\n<p>\nThis news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.\n<\/p>\n<p>\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2021 and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=52639165&amp;newsitemid=20220401005105&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=91f59170b3a8e0b0b8ef7c414286768b\">www.sec.gov<\/a>).\n<\/p>\n<p>\n  <b>Please see Prescribing Information for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvaxneuvance%2Fvaxneuvance_pi.pdf&amp;esheet=52639165&amp;newsitemid=20220401005105&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvaxneuvance%2Fvaxneuvance_pi.pdf&amp;index=8&amp;md5=265e573fad8bf97a7d272be713783404\">https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vaxneuvance\/vaxneuvance_pi.pdf<\/a>.<\/b>\n<\/p>\n<p>\n  <b>and Patient Information at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvaxneuvance%2Fvaxneuvance_ppi.pdf&amp;esheet=52639165&amp;newsitemid=20220401005105&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvaxneuvance%2Fvaxneuvance_ppi.pdf&amp;index=9&amp;md5=03956c807b1680a3942b313c0b89c8f5\">https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vaxneuvance\/vaxneuvance_ppi.pdf<\/a>.<\/b>\n<\/p>\n<p>\n  <img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220401005105r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n  <span class=\"bwct31415\"><\/span>\n<\/p>\n<p id=\"mmgallerylink\">\n  <span id=\"mmgallerylink-phrase\">View source version on <a href=\"http:\/\/businesswire.com\">businesswire.com<\/a>: <\/span><br \/>\n  <span id=\"mmgallerylink-link\"><br \/>\n    <a href=\"https:\/\/www.businesswire.com\/news\/home\/20220401005105\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20220401005105\/en\/<\/a><br \/>\n  <\/span>\n<\/p>\n<p>\nMedia:<br \/>\n<br \/>Melissa Moody<br \/>\n<br \/>(215) 407-3536\n<\/p>\n<p>\nKimberly Petrillo<br \/>\n<br \/>(267) 742-2813\n<\/p>\n<p>\nInvestors:<br \/>\n<br \/>Peter Dannenbaum<br \/>\n<br \/>(908) 740-1037\n<\/p>\n<p>\nAlexis Constantine<br \/>\n<br \/>(908) 740-1051\n<\/p>\n<p>Source: Merck &amp; Co., Inc.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date of the supplemental biologics license application (sBLA) for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in infants and children to July 1, 2022. The FDA requested additional analyses of data from the pediatric studies, which Merck has submitted to the FDA. No new studies have been requested by the FDA. In December 2021, Merck announced that the FDA accepted the company\u2019s application for VAXNEUVANCE for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age and it was granted Priority Review. \u201cWe are confident in the strength of the data from our pediatric studies with VAXNEUVANCE and will continue to work expeditiously with the FDA to bring this important vaccine forward to infants and children in the United States as soon as possible,\u201d said<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289,57],"class_list":["post-3596655","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release","tag-vaccine-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date of the supplemental biologics license application (sBLA) for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in infants and children to July 1, 2022. The FDA requested additional analyses of data from the pediatric studies, which Merck has submitted to the FDA. No new studies have been requested by the FDA. In December 2021, Merck announced that the FDA accepted the company\u2019s application for VAXNEUVANCE for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age and it was granted Priority Review. \u201cWe are confident in the strength of the data from our pediatric studies with VAXNEUVANCE and will continue to work expeditiously with the FDA to bring this important vaccine forward to infants and children in the United States as soon as possible,\u201d said\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-08T04:39:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220401005105r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\\\/\",\"name\":\"Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220401005105r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2022-04-01T10:45:00+00:00\",\"dateModified\":\"2025-03-08T04:39:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220401005105r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220401005105r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/","og_locale":"en_US","og_type":"article","og_title":"Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date of the supplemental biologics license application (sBLA) for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in infants and children to July 1, 2022. The FDA requested additional analyses of data from the pediatric studies, which Merck has submitted to the FDA. No new studies have been requested by the FDA. In December 2021, Merck announced that the FDA accepted the company\u2019s application for VAXNEUVANCE for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age and it was granted Priority Review. \u201cWe are confident in the strength of the data from our pediatric studies with VAXNEUVANCE and will continue to work expeditiously with the FDA to bring this important vaccine forward to infants and children in the United States as soon as possible,\u201d said","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/","og_site_name":"Merck.com","article_modified_time":"2025-03-08T04:39:59+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220401005105r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/","name":"Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220401005105r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","datePublished":"2022-04-01T10:45:00+00:00","dateModified":"2025-03-08T04:39:59+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220401005105r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220401005105r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"30892af6-9776-40aa-b4c1-a0389e9735b2","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_multimedia\/Merck_Logo_Horizontal_Teal-Grey_RGB.jpg","size":"211320","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Provides-Update-on-FDA-Review-of-Supplemental-Biologics-License-Application-for-VAXNEUVANCE-Pneumococcal-15-valent-Conjugate-Va-AE8G9.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3596655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3596655\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=3596655"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=3596655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}